LAPTM4B allele *2 is a marker of poor prognosis following hepatic tumor resection for hepatocellular carcinoma

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Yang, Hua ^a   Zhai, Guojun ^b   Ji, Xiaoxu ^b   Xiong, Fuxia ^c   Su, Jing ^a   McNutt, Michael A ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY THIRD HOSPITAL   (China)

^c LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALLELE; ARTICLE; CANCER SURVIVAL; CLINICAL FEATURE; CORRELATIONAL STUDY; DISEASE FREE SURVIVAL; FEMALE; GENOTYPE; HUMAN; LAPTM4B GENE; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROGNOSIS; RISK FACTOR; TUMOR GENE; BLOOD; GENETIC ASSOCIATION; GENETICS; KAPLAN MEIER METHOD; LIVER TUMOR; MIDDLE AGED;

LAPTM4B PROTEIN, HUMAN; MEMBRANE PROTEIN; ONCOPROTEIN;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; ONCOGENE PROTEINS; PROGNOSIS;

EID: 84859247313     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034984     Document Type: Article

References (26)

1. El-Serag HB, Rudolph KL, (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576.
2. Howe HL, Wingo PA, Thun MJ, Ries LA, Rosenberg HM, et al. (2001) Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. Journal of the National Cancer Institute 93: 824-842.
3. Landis SH, Murray T, Bolden S, Wingo PA, (1998) Cancer statistics, 1998. CA: a cancer journal for clinicians 48: 6-29.
4. Llovet JM, Burroughs A, Bruix J, (2003) Hepatocellular carcinoma. Lancet 362: 1907-1917.
5. Farazi PA, DePinho RA, (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nature reviews 6: 674-687.
6. Suriawinata A, Xu R, (2004) An update on the molecular genetics of hepatocellular carcinoma. Seminars in liver disease 24: 77-88.
7. Shao GZ, Zhou RL, Zhang QY, Zhang Y, Liu JJ, et al. (2003) Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene 22: 5060-5069.
8. Yang H, Xiong F, Qi R, Liu Z, Lin M, et al. (2010) LAPTM4B-35 is a novel prognostic factor of hepatocellular carcinoma. Journal of surgical oncology 101: 363-369.
9. Yang H, Xiong FX, Lin M, Yang Y, Nie X, et al. (2010) LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma. Journal of cancer research and clinical oncology 136: 275-81.
10. Yin M, Xu Y, Lou G, Hou Y, Meng F, et al. (2011) LAPTM4B overexpression is a novel predictor of epithelial ovarian carcinoma metastasis. International journal of cancer 129: 629-635.
11. Zhou L, He XD, Chen J, Cui QC, Qu Q, et al. (2007) Overexpression of LAPTM4B-35 closely correlated with clinicopathological features and post-resectional survival of gallbladder carcinoma. Eur J Cancer 43: 809-815.
12. Yang Y, Yang H, McNutt MA, Xiong F, Nie X, et al. (2008) LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma. Oncology reports 20: 1077-1083.
13. Zhou L, He XD, Cui QC, Zhou WX, Qu Q, et al. (2008) Expression of LAPTM4B-35: a novel marker of progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma. Cancer letters 264: 209-217.
14. Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, et al. (2010) Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nature medicine 16: 214-218.
15. Li L, Wei XH, Pan YP, Li HC, Yang H, et al. (2010) LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling. Oncogene 29: 5785-5795.
16. Yang H, Xiong F, Wei X, Yang Y, McNutt MA, et al. (2010) Overexpression of LAPTM4B-35 promotes growth and metastasis of hepatocellular carcinoma in vitro and in vivo. Cancer letters 294: 236-244.
17. Zhou L, He XD, Yu JC, Zhou RL, Xiong FX, et al. (2010) Expression of LAPTM4B in gallbladder carcinoma cells: the role in invasive potential. Hepato-gastroenterology 57: 207-211.
18. Zhou L, He XD, Yu JC, Zhou RL, Yang H, et al. (2010) Overexpression of LAPTM4B promotes growth of gallbladder carcinoma cells in vitro. American journal of surgery 199: 515-521.
19. Meng F, Song H, Luo C, Yin M, Xu Y, et al. (2011) Correlation of LAPTM4B polymorphisms with cervical carcinoma. Cancer 117: 2652-2658.
20. Wang S, Zhang QY, Zhou RL, (2011) Relationship between LAPTM4B gene polymorphism and susceptibility of primary liver cancer. Ann Oncol doi:10.1093/annonc/mdr538.
21. Liu Y, Zhang QY, Qian N, Zhou RL, (2007) Relationship between LAPTM4B gene polymorphism and susceptibility of gastric cancer. Ann Oncol 18: 311-316.
22. Cheng XJ, Xu W, Zhang QY, Zhou RL, (2008) Relationship between LAPTM4B gene polymorphism and susceptibility of colorectal and esophageal cancers. Ann Oncol 19: 527-532.
23. Zhai G, Yang H, Ji X, Xiong F, Su J, et al. (2011) Correlation of LAPTM4B polymorphisms with hepatocellular carcinoma in Chinese patients. Medical oncology doi:10.1007/s12032-011-0139-y.
24. Yang H, Zhai G, Ji X, Xiong F, Su J, et al. (2011) Correlation of LAPTM4B polymorphisms with gallbladder carcinoma susceptibility in Chinese patients. Medical oncology doi:10.1007/s12032-012-0173-4.
25. Zhou L, He XD, Yu JC, Zhou RL, Shan Y, et al. (2011) Overexpression of LAPTM4B-35 attenuates epirubucin-induced apoptosis of gallbladder carcinoma GBC-SD cells. Surgery 150: 25-31.
26. Liu X, Xiong F, Wei X, Yang H, Zhou R, (2009) LAPTM4B-35, a novel tetratransmembrane protein and its PPRP motif play critical roles in proliferation and metastatic potential of hepatocellular carcinoma cells. Cancer science 100: 2335-2340.